Previous 10 | Next 10 |
Chinese biotech I-Mab ( NASDAQ: IMAB ) on Tuesday said it got local regulatory approval to start a phase 3 trial evaluating its antibody lemzoparlimab in combination with cancer drug azacitidine for the treatment of myelodysplastic syndrome (MDS). MDS is a group of cancers...
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome PR Newswire GAITHERSBURG, Md. and SHANGHAI , Sept, 13, 2022 /PRNewswire/ -- I-Mab (th...
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 PR Newswire Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patient...
I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 PR Newswire Abstract summarizing lemzoparlimab Phase 2 data selected for proffered paper presentation on September 10 Investor conference call ...
Summary Using its animal models, Biocytogen has also developed an innovative in vivo drug efficacy and safety screening process to discover 10+ preclinical and clinical candidates, a collection of monoclonal antibodies, bispecific antibodies and bispecific ADCs. I-Mab said it woul...
I-Mab ( NASDAQ: IMAB ) and senior management using their own personal funds may purchase up to $40M worth of the company's American Depository Shares on the open market . The buys are part of a share repurchase program previously authorized by the company's board. ...
I-Mab Announces Share Purchase Plans by the Company and the Senior Management PR Newswire GAITHERSBURG, Md. and SHANGHAI , Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company commit...
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022 PR Newswire - M ajor updates will focus on global clinical development of core assets, upcoming milestones and financial results - ...
Gainers: Blue Water Vaccines ( BWV ) +57% . Eargo ( EAR ) +49% . Cassava Sciences ( SAVA ) +29% . MiNK Therapeutics ( INKT ) +24% . Cogent Biosciences ( COGT ) +16% . Losers: Blueprint Medicines ( BPMC ) -22% ....
Chinese biotech I-Mab ( NASDAQ: IMAB ) on Tuesday said its U.S. partner AbbVie ( ABBV ) would discontinue a phase 1b study evaluating a combination treatment including its anti-CD47 antibody therapy lemzoparlimab for two types of cancers. ABBV stock and U.S.-listed share...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...